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Free fatty acid receptor 2 (FFA2; GPR43) is a G protein-cou-
pled seven-transmembrane receptor for short-chain fatty acids
(SCFAs) that is implicated in inflammatory and metabolic dis-
orders. The SCFA propionate has close to optimal ligand effi-
ciency for FFA2 and can hence be considered as highly potent
given its size. Propionate, however, does not discriminate
between FFA2 and the closely related receptor FFA3 (GPR41).
To identify FFA2-selective ligands and understand the molecu-
lar basis for FFA2 selectivity, a targeted library of small carbox-
ylic acids was examined using holistic, label-free dynamic mass
redistribution technology for primary screening and the recep-
tor-proximal G protein [35S]guanosine 5-(3-O-thio)triphos-
phate activation, inositol phosphate, and cAMP accumulation
assays for hit confirmation. Structure-activity relationship anal-
ysis allowed formulation of a general rule to predict selectivity
for small carboxylic acids at the orthosteric binding site where
ligands with substituted sp3-hybridized -carbons preferen-
tially activate FFA3, whereas ligands with sp2- or sp-hybridized
-carbons prefer FFA2. The orthosteric binding mode was ver-
ified by site-directed mutagenesis: replacement of orthosteric
site arginine residues by alanine in FFA2 prevented ligand bind-
ing, and molecular modeling predicted the detailed mode of
binding. Based on this, selective mutation of three residues to
their non-conserved counterparts in FFA3 was sufficient to
transfer FFA3 selectivity to FFA2. Thus, selective activation of
FFA2 via the orthosteric site is achievable with rather small
ligands, a finding with significant implications for the rational
design of therapeutic compounds selectively targeting the SCFA
receptors.
The seven-transmembrane G protein-coupled receptor
FFA2,6 previously named GPR43, is expressed primarily on
neutrophils, eosinophils, and other immune cells and responds
to short-chain fatty acids (SCFAs) (1), which are produced in
high concentrations bymicrobial fermentation in the colon (2).
The receptor plays a critical role in neutrophil recruitment dur-
ing intestinal inflammation (3), and FFA2-deficient mice show
exacerbated or unresolved inflammation in colitis, arthritis,
and asthma models, indicating that FFA2 can provide a molec-
ular link between fermentable dietary fiber and its beneficial
effects on colitis and inflammation (4). These studies suggest
that FFA2 is important in the regulation of intestinal inflamma-
tion and that the receptormight represent a new drug target for
the treatment of inflammatory bowel disease. The receptor is
also believed to play a role in energy homeostasis and appetite
regulation (5). Further studies, however, are necessary to firmly
establish these novel links, and such studies will depend criti-
cally on the availability of selective agonists and antagonists for
the receptor.
FFA2 and the closely related receptor FFA3 (GPR41) respond
to SCFAs at high micromolar and millimolar concentrations
with propionate being the most potent agonist for both recep-
tors (6–8). Together with the medium- and long-chain free
fatty acid receptor FFA1 (GPR40), the receptors form a subfam-
ily capable of sensing free fatty acids in concentrations corre-
sponding to elevated physiological levels (1, 9). Although the
molar potency of the SCFAs on FFA2 and FFA3 must be
regarded as low, the compounds are also very small. Ligand
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efficiency (LE) is a recently introduced concept that assists lead
selection by calculating binding energy per non-hydrogen atom
as smaller, potent leads increase the likelihood of generating
drug candidates with appropriate pharmacokinetic character-
istics (10, 11). LE has become popular in evaluation of early
leads and is especially widespread in fragment-based drug dis-
covery where such small ligands are grown or assembled to
larger and more potent leads (12, 13). Analysis of successful
drugs has suggested that an LE of g  0.3 kcal mol1 per
non-hydrogen atom is desirable, and empirical analysis has
concluded that themaximal free energy contribution per heavy
atom for non-metal ligands is around1.5 kcalmol1 per non-
hydrogen atom (14). Notably, acetate (C2) and propionate (C3)
already have ligand efficiencies close to this value at FFA2 and
FFA3 and can therefore be regarded as highly potent for their
size (Table 1). Thus, it is unrealistic to expect that the potency
of the SCFAs can be increased without at the same time con-
siderably increasing the size of the compounds. It is unclear,
however, whether the orthosteric binding site can accommo-
date significantly larger ligands. A detailed understanding of
the interactions of the SCFAs in the orthosteric binding site is
expected to indicate the prospects for this strategy and to assist
the rational design of larger, more potent and selective modu-
lators of FFA2 and FFA3.
Previous structure-activity relationship (SAR) studies have
found FFA2 to exhibit a preference for smaller SCFAs than does
FFA3with a rank order of potency of acetate (C2) propionate
(C3) butyrate (C4) valerate (C5) formate (C1) for FFA2
andC3C4C5C2 caproate (C6) for FFA3 (15). A series
of FFA2-selective allosteric agonists that exhibit positive coop-
erativity with SCFAs has also been disclosed (16, 17). Although
these compounds certainly represent useful tools for further
pharmacological studies of FFA2, because they bind to a site or
sites distinct from the orthosteric binding pocket, it is possible
that they may generate signals that are not identical to those
triggered by SCFAs. Themoderate solubility andmetabolic lia-
bility of these allosteric compounds furthermore represent a
limitation to their use (17). In the present study, we explored
the potential of small carboxylic acids (SCAs) as pharmacolog-
ical tools and further investigated their interaction with the
orthosteric binding site. To date, only a small number of satu-
rated straight and branched SCAs have been investigated as
ligands at these receptors. Here we report the results from
structure-activity investigations of an expanded set of SCAs,
including carboxylic acids with additional branched, unsatu-
rated, and cyclic tails. The studies led to the identification of
selective orthosteric ligands for both FFA2 and FFA3 and to the
elucidation of a general rule to predict the FFA2/FFA3 selectiv-
ity of SCAs. Furthermore, this rule was validated by molecular
modeling and site-directed mutagenesis at FFA2, resulting in
the reversal of selectivity between FFA2 and FFA3 ligands at the
mutated receptor.
EXPERIMENTAL PROCEDURES
Materials—Materials for cell culture were purchased from
Invitrogen. Cell culture-compatible Epic biosensor micro-
plates and compound source plates were from Corning Inc.
Restriction endonucleases and modifying enzymes were
from New England Biolabs, and all other laboratory reagents
were obtained from Sigma-Aldrich unless otherwise speci-
fied. The radiochemical [35S]GTPS was from PerkinElmer
Life Sciences.
Formic acid (C1), acetic acid (C2), propionic acid (C3),
butyric acid (C4), valeric acid (C5), methylthioacetic acid (1),
3-methylbutyric acid (2), pivalic acid (3), 2-methylbutyric
acid (4), cyclopropylcarboxylic acid (5), cyclobutylcarboxylic acid
(6), 1-methylcyclopropanecarboxylic acid (7), vinylacetic acid
(9), 3-pentenoic acid (12), acrylic acid (13), propiolic acid (14),
2-butynoic acid (15), trans-crotonic acid (16), 2-methylacrylic
acid (18), 3-methylcrotonic acid (19), trans-2-methylcrotonic
acid (20), cyclopent-1-enecarboxylic acid (22), trifluoroace-
tic acid (23), 3-bromopropionic acid (24), ()-2-methylcyclo-
propanecarboxylic acid (25; 1:4 mixture of diastereomers),
1-cyanocyclopropanecarboxylic acid (26), pyruvic acid (27),
and ()-2-phenylpropionic acid (28) were purchased from Sig-
ma-Aldrich. Angelic acid (21) was purchased from ABCR
(Karlsruhe, Germany). Cyclopropylacetic acid (8) was pur-
chased fromAlfa Aesar. 3-Butynoic acid (10), 3-pentynoic acid
(11), and cis-crotonic acid (17) were synthesized as described in
the supplemental methods. The identity and purity of all com-
pounds were confirmed by 1H and 13C NMR.
Plasmid Construction—The Flp recombinase-mediated ho-
mologous recombination system (Flp-InTM T-RExTM, Invitro-
gen) was used to generate cell lines stably expressing human
FFA2 and FFA3 in a doxycycline-dependent manner. The cod-
ing sequences of FFA2 and FFA3 were subcloned from
pcDNA3.1 (Invitrogen) into the inducible expression vector
pcDNA5/FRT/TO (Invitrogen) via 5 HindIII and 3 XhoI.
Veracity of the constructs was confirmed by restriction endo-
nuclease digestion. Cloning and generation of enhanced yellow
fluorescent protein-tagged versions of human FFA2 and FFA3
(FFA2-eYFP and FFA3-eYFP) and various binding mutants
have been described elsewhere (18).
Cell Culture and Generation of Stable Flp-In T-REx HEK293
Cells—Flp-In T-REx cells weremaintained in high glucoseDul-
becco’s modified Eagle’s medium (DMEM) supplemented with
10% (v/v) fetal bovine serum, 1% penicillin/streptomycin mix-
ture, and 15 g/ml blasticidin at 37 °C and 5% CO2 in a humid-
ified atmosphere.
To generate Flp-In T-REx 293 cells able to inducibly express
a receptor of interest, the cells were transfected with a 1:9 mix-
ture of the desired receptor cDNA in pcDNA5/FRT/TO vector
and the pOG44 vector (Invitrogen’s expression vector for Flp
recombinase) using a calcium phosphate DNA precipitation
method according to the manufacturer’s instructions. After
48 h, the medium was changed to medium supplemented with
100 g/ml hygromycin B (InvivoGen, Toulouse, France) to ini-
tiate selection of stably transfected cells. Expression of the
appropriate construct from the Flp-In locus was induced by
treatment with 1 g/ml doxycycline (Sigma) for 16 h.
Dynamic Mass Redistribution (DMR) Assays (Corning Epic
Biosensor)—DMR assays were performed on a beta version of
theCorning Epic biosensor. A description and validation of this
method is detailed in Schro¨der et al. (19). Briefly, cells were
grown in Epic microplates, which are equipped with a resonant
wave guide grating biosensor. GPCR signaling-induced mass
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redistribution, due to relocation of cellular constituents, leads
to a change of the optical density in cells. This phenomenon can
be detected by passing polarized broadband light through the
bottom portion of cells and measuring changes in wavelength
of the outgoing light. The wavelength shift (in picometers) is
directly proportional to the amount of DMR.
For Epic assays, HEK Flp-In T-REx cells were seeded onto
fibronectin-coated 384-well Epic sensor microplates at a den-
sity of 15,000 cells/well to obtain confluent monolayers. After
cultivation for 20–24h (at 37 °C and 5%CO2) cellswerewashed
with Hanks’ balanced salt solution containing 20 mM HEPES
and kept for 1 h at 28 °C in the Epic reader to allow for temper-
ature equilibration. The sensor plate was then scanned to
obtain a base-line optical signature. Finally, compound solu-
tions were transferred into the sensor plate with an integrated
liquid handling device, and cell responses were recorded con-
tinuously for at least 3600 s. All data were normalized to the
responses induced by 300 M propionic acid, which were set to
100%.
[35S]GTPS G Protein Activation Assays—Membranes ex-
pressing wild type or mutant versions of human FFA2-eYFP or
FFA3-eYFP were prepared from stable cell lines using
0.5 g/ml doxycycline (24 h) as described elsewhere (20).
[35S]GTPS binding assays were performed essentially as
described (20). Briefly, 5 g of cell membranes were preincu-
bated for 15 min at 25 °C in assay buffer (50 mM Tris-HCl, pH
7.4, 10mMMgCl2, 100mMNaCl, 1 mM EDTA, 1MGDP, 0.5%
fatty acid-free BSA) containing the indicated concentrations
of ligands. Binding was initiated by addition of 50 nCi of
[35S]GTPS to each tube, and the reactionwas terminated after
1-h incubation by rapid filtration through GF/C glass filters
using a 24-well Brandel cell harvester (Alpha Biotech, Glasgow,
UK). Unbound radioligand was washed from filters by three
washes with ice-cold wash buffer (50 mM Tris-HCl, pH 7.4, 10
mMMgCl2), and [35S]GTPS binding was determined by liquid
scintillation spectrometry. Membrane expression of each re-
ceptor was assessed by measurement of enhanced yellow fluo-
rescent protein (eYFP) using a PHERAstar FS microplate
reader (excitation, 485 nm; emission, 520 nm; BMG Labtech,
Offenburg, Germany).
cAMP Accumulation Assays—Inhibition of forskolin-stimu-
lated cAMP accumulation in FFA3 cells was monitored with
the MithrasLB 940 multimode reader (Berthold Technologies,
Bad Wildbad, Germany) using the HTRF-cAMP dynamic kit
(CIS Bio International, Gif-sur-Yvette Cedex, France) accord-
ing to the manufacturer’s instructions. For the assay, cells were
resuspended in assay buffer (Hanks’ balanced salt solution, 20
mM HEPES, 1 mM 3-isobutyl-1-methylxanthine) and trans-
ferred to 384-well small volumemicroplates (Greiner Bio-One,
Frickenhausen, Germany) at a density of 50,000 cells/well.
Plates were incubated for 30 min at 37 °C before compounds
were added in the presence of 5 M forskolin. After further
incubation for 30 min at 37 °C, the reactions were stopped by
adding 1.25% Triton X-100 containing HTRF reagents. Plates
were then incubated for 60min at room temperature, and time-
resolved FRET signals were measured after excitation at 320
nm. Both the emission signal from the europium cryptate-la-
beled anti-cAMP antibody (620 nm) and the FRET signal
resulting from the labeled cAMP-d2 (665 nm) were recorded.
Results were calculated from the 665/620 nm ratio and ex-
pressed as F (F %  ((Standard or sample ratio  Rationeg)/
Rationeg) 	 100). All data were normalized to the functional
response obtained with 300 M propionic acid.
Inositol Monophosphate (IP1) Accumulation Assays—The
HTRF-IP One kit (CIS Bio International) was used for mea-
suring IP1 production in cells expressing FFA2. In a 384-well for-
mat, the cell suspension was dispensed at 100,000 cells/7
l/well. After 20-min incubation at 37 °C, 7 l of stimulation
buffer (Hanks’ balanced salt solution, 10 mM HEPES, 50 mM
LiCl) containing various concentrations of ligand were added.
After further incubation at 37 °C for 30 min, 3 l of IP1-d2
conjugate followed by 3 l of europium cryptate-labeled anti-
IP1 antibody were added. Time-resolved fluorescence at 620
and 665 nmwas measured with theMithras LB 940multimode
reader after incubation at room temperature for 60min, and the
ratios of the signals expressed as F were calculated as
described above. Data were normalized to the IP1 response
obtained with 300 M propionic acid.
Molecular Modeling and Ligand Docking—Homology mod-
eling of hFFA2 and hFFA3 receptors using the 2-adrenergic
receptor (ProteinData Bank code 2RH1) as a template was con-
ducted using MOE software (Molecular Operating Environ-
ment, 2009, Chemical Computing Group, Inc., Montreal,
Quebec, Canada) with a default homology modeling protocol.
Selection of homology models was based on the location of
extracellular loop 2 (ECL2). Only models where ECL2 was
located relatively similarly to the available crystal structures of
the ligand-bound GPCRs were considered for docking. Thus,
ECL2 conformations that prevented entrance to the putative
binding cavity were excluded for the next steps. The available
model of FFA1 (21), with the side-chain conformers optimized
according to mutagenesis data for HisVI:16/4.56, ArgV:05/
5.39, HisVI:20/6.55, and ArgVII:02/7.35, was used to optimize
the rough homology models of hFFA2 and hFFA3 obtained.
Docking of SCAs into these models and those containing pro-
posed mutants was performed using the Glide module of
Schro¨dinger software (22). The Glide docking box included the
cavity between transmembrane helices 3, 5, and 6 involving
residues at positions V:05/5.39, VII:02/7.35, and VI:20/6.55,
which we have shown to be crucial for anchoring the carboxyl
group of fatty acids (18). The Glide default settings with the
extraprecision scoring option were used for docking. Images
were prepared using the Maestro 8.5 interface (23).
Data Analysis—All data were quantified, grouped, and ana-
lyzed using GraphPad Prism 5.02 and are expressed as mean
S.E. Data were fit to both three-parameter (fixedHill slope) and
four-parameter non-linear regression isotherms. The three-pa-
rameter curve fit was statistically appropriate in all cases.
RESULTS
Characterization of Assays for Primary and Secondary
Screening—FFA2 and FFA3 clearly mediate distinct physiolog-
ical and pathological outcomes (1), yet the absence of selective
ligands for these receptors has hampered further pharmacolog-
ical studies of their individual functions. Both receptors couple
to the Pertussis toxin-sensitive Gi/o family of G proteins,
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whereas FFA2 additionally couples to the Gq/11 family (6–8,
18). To avoid any potential bias in our assay results due to func-
tional selectivity of tested ligands, we used the holistic, label-
free Epic DMR assay, which monitors integrated traffic in the
cell in real time without the need for epitope tagging or specific
receptor probes (19, 24). Previously, we have demonstrated that
DMR is a powerful assay platform for discerning the individual
pathways activated by different GPCRs from all four G protein
classes (Gi/o, Gs, Gq/11, and G12/13) and is therefore unbi-
ased yet also pathway-sensitive (19). Thus, we initially tested
the standard straight-chain orthosteric FFA2/FFA3 agonists,
formate (C1), acetate (C2), propionate (C3), butyrate (C4), and
valerate (C5), using the Epic DMR assay and compared these
results with those obtained with the traditional [35S]GTPS
binding assay, which measures predominantly Gi/o G protein
activation (and hence is appropriate for both FFA2 and FFA3
signaling). In addition, second messenger accumulation in
whole cells was examined using IP1 assays for FFA2 and cAMP
accumulation assays for FFA3.
Stimulation of Flp-In T-REx 293 cells stably transfected to
express human FFA2 on demand resulted in positive deflec-
tions in DMR in a concentration-dependent manner (Fig. 1A),
the peaks of which can be converted into log concentration-
response curves to determine potency and efficacy for each
agonist (Fig. 1C, red symbols, and Table 1). Notably, the DMR
traces obtained for the same ligands at FFA2 (Fig. 1A) or FFA3
(Fig. 1B) were qualitatively different, indicating the involve-
ment of non-identical signaling pathways and corroborating
previous studies using traditional second messenger assays
(6–8, 18, 20). Millimolar activity of formate (C1) on FFA2 was
confirmed (7), but no activity was observed on FFA3 at up to 10
mM. In accordancewith previous results, acetate (C2) wasmore
than an order of magnitude more potent on FFA2, whereas
propionate (C3) was the most potent SCFA and equipotent at
each receptor (Fig. 1C and Table 1). Butyrate (C4) and valerate
(C5) exhibited modest selectivity for FFA3 and in the case of
valerate with lower efficacy than C3 also in agreement with
other reports (6, 7).
Examination of each of C1–C5 in traditional assays of recep-
tor activation resulted in a similar pattern of selectivity (Fig. 1,D
and E, and Table 1), although as expected for signals with dif-
ferent levels of amplification and for comparisons between
intact cells and cell membrane assays, absolute values of
potency varied somewhat. Despite this, C1 and C2 had marked
FIGURE 1. Short-chain fatty acid responses at FFA2 and FFA3 receptors. Signaling in response to the SCFAs formate (C1), acetate (C2), propionate (C3),
butyrate (C4), and valerate (C5) in Flp-In T-REx 293 cells stably expressing either human FFA2 or FFA3 was assessed by measuring DMR in a Corning Epic
biosensor. A and B, wavelength shift in picometers (pm) over time (seconds) was assessed upon stimulation with increasing concentrations of ligand as
indicated at FFA2 (A) and FFA3 (B). Shown are representative traces from a single experiment representative of three separate experiments. C, concentration-
response curves were constructed from the maximum (max) wavelength shift per concentration normalized to C3 at the corresponding receptor, thereby
allowingcomparisonof ligand selectivity at FFA2 (red circles) versusFFA3 (blue squares). Data aremeanS.E.,n3.D, concentration-response curveswere also
generated using the [35S]GTPS binding assay to enable comparison of receptor selectivity usingDMRwith amore traditional GPCR readout. Data aremean
S.E., n 3. E, comparison of concentration-response curves from cAMP (FFA3) and IP1 (FFA2) second messenger assays. Data are mean S.E., n 3.
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selectivity for FFA2 over FFA3 (pEC50 of 1.8 and 1.3 for
C1 andC2, respectively, where positivepEC50 indicates selec-
tivity for FFA2 and a negative number represents FFA3 selec-
tivity). LEs were calculated using an average of the experimen-
tally determined pEC50 values and indicate that C2 and C3 do
indeed have LE values close to the maximal value (Table 1).
Selection and Evaluation of Compounds—SCAs with lipo-
philic hydrocarbon tails consisting of four or fewer carbon
atoms, including cyclic and unsaturated compounds with well
defined three-dimensional structure, were selected to thor-
oughly explore the binding site of FFA2. We screened these
SCAs at a single concentration of 300 M using the Epic DMR
(Fig. 2). None of the noted chemicals produced significant
DMR responses in native HEK 293 cells lacking expression of
either FFA2 or FFA3 (Fig. 2A). A large proportion of the SCAs
tested displayed activity, however, at either or both FFA2 (Fig.
2B) and FFA3 (Fig. 2C). SCAs with polar substituents, like 26
and 27, or larger structures, like 28, were close to inactive on
both receptors. Ligands that generated negative DMR signals
were not pursued further, whereas the majority of the active
compounds were then further explored with both full concen-
tration-response curves in the DMR assay and at [35S]GTPS
binding and appropriate second messenger pathways (Table 1
and below) after being subdivided into groups based upon their
structure to enable SAR investigation.
Branched and Cyclic Compounds—Receptor selectivity and
SAR were examined with branched and cyclic SCAs using the
Epic DMR assay (Fig. 3A) and conventional signaling assays
(Table 1 and Fig. 3B). Isobutyrate, isovalerate (2), and pivalate
(3), representing bulkier methyl-substituted analogs of propio-
nate and butyrate, have previously been reported to be at least
an order of magnitude more selective for FFA3 over FFA2 (7).
TABLE 1
Agonist activities of small carboxylic acids on hFFA2 and hFFA3, calculated ligand efficiencies, and average selectivities
Data are mean S.E., n 3.
a DMR assay using the Corning Epic biosensor.
b LE is calculated by the formulagG/Nnon-hydrogen atoms whereG RTln(KD) presuming that KD
 EC50. The average of pEC50 values from at least two differ-
ent assays was used in the calculation. Values are given as kcal mol1 atom1.
c Selectivity (calculated by pEC50 pEC50,FFA2 pEC50,FFA3) is based on the average pEC50 values of the available assays.
d n.a., not assessed.
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We also found these ligands to be selective for FFA3 over FFA2
(pEC50 0.4 for 2 and 0.7 for 3; Fig. 3, A and B, and
Table 1), and this relationship extended to sec-valerate (4;
pEC50 0.7; Fig. 3, A and B). Interestingly, although selec-
tive for FFA3, both 2 and 4were poorly efficacious at this recep-
tor in the DMR assay, an observation that was consistent at the
other signaling assays for 4 but not 2. Cyclopropylcarboxylate
(5), a somewhat bulkier analog ofC3, exhibitedmoderate selectiv-
ity for FFA3, which was maintained upon replacing the cyclopro-
pylwith cyclobutyl (6). Thebulky cyclopropyl analog (7)was equi-
potentwithC3onFFA3 andwas30-fold selective for FFA3over
FFA2.Asimilar selectivitywasobserved for thecyclopropyl analog
8. In each instance these ligands displayed close to full agonism at
FFA3 (Fig. 3, A and B, and Table 1). Based upon these findings,
branched and cyclic SCAs appear to be selective for FFA3 over
FFA2 at a variety of signaling readouts.
Non-conjugated Unsaturated Compounds—Introduction of
a terminal double bond in C4 (9) resulted in preserved FFA3
activity and slightly increased selectivity over FFA2 compared
with C4 (pEC50 0.7; Fig. 3, A and B, and Table 1), whereas
FIGURE 2. Screening of small carboxylic acids using DMR. Cells either lacking both FFA2 and FFA3 (HEK293 cells; A) or expressing FFA2 (B) or FFA3 (C) were
stimulated with a 300 M concentration of individual SCAs or positive controls (SCFAs C1, C2, C3, and C5) and DMR-monitored over a 60-min period. B, panel
i, DMR traces for SCAs over time at FFA2. B, panel ii, maximum (max) wavelength shift (pm) achieved at FFA2 during the length of the assay for each SCA in
triplicate. C, DMR traces (panel i) and maximumwavelength shift (panel ii) for the FFA3 counterscreen. Data are mean S.E., n 3.
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introduction of a terminal alkyne (10), which produces a con-
strained and distinctly shapedC4 analog, resulted in an order of
magnitude lower activity on both receptors while maintaining
selectivity for FFA3 (pEC500.4; Fig. 3,A and B). The poor
potency of 10 resulted in loss of signal in the [35S]GTPS bind-
ing assay (Table 1). Greatest selectivity for FFA3 in the Epic
DMRand secondmessenger assayswas achievedwith the rigid-
ified unsaturated analog 12 (pEC50  1.4; Fig. 3, A and B).
Interestingly, 12 displayed higher efficacy on FFA3 in the
receptor-proximal [35S]GTPS assay, yet the potency of 12 at
each receptor was equivalent (Table 1). Regardless, compound
12 is also instructive because it demonstrates that a rigidly
extended C4 tail can be contained within the binding sites of
both receptors.
Conjugated Unsaturated Compounds—Acrylate (13) repre-
sents a narrower analog of propionate and exists preferentially
in a flat conformation because of the conjugation between the
alkene and the carboxylic acid. This compound was a full ago-
FIGURE 3. Structure-activity relationships of branched, cyclic, and non-conjugated unsaturated SCAs at FFA2 and FFA3. A, DMR maximum (max)
response (pm) concentration-response curves to branched/cyclic (panels i–vi) and non-conjugated unsaturated (panels vii–ix) SCAs (chemical structures are
inset) were generated in cells stably expressing either FFA2 (circles) or FFA3 (squares). Data aremean S.E.,n 3.B, concentration-response curves of the same
chemical series in IP1 (FFA2) and cAMP (FFA3) assays. Data are mean S.E., n 3.
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nist at both FFA2 and FFA3 but was moderately selective for
FFA2 (pEC50  0.7; Fig. 4, A and B). Introduction of a triple
bondwith propargylate (14) resulted in a ligandmarkedlymore
selective for FFA2 (pEC50 1.3; Fig. 4, A and B, and Table 1)
with little to no activity observed in either the Epic DMR assay
or secondmessenger assays for FFA3. For FFA2, methyl substi-
tutions were accommodated at all positions on acrylate (16-20)
(Fig. 4, A and B, and Table 1). In contrast, FFA3 was far less
tolerant to conjugated unsaturated compounds. Of the ligands
tested, trans-3-methyl (16), cis-3-methyl (17), and 2-methyl
(18) substitutions weremoderately active with reduced efficacy
and, for 17, reduced potency in both the DMR and signaling
assays (pEC50 0.6). The terminally dimethyl-substituted 19
maintained the selectivity of 17, whereas 2,3-cis-dimethylacry-
late (20) and 2,3-trans-dimethylacrylate (21) both exhibited
100-fold selectivity for FFA2 (Fig. 4, A and B, and Table 1).
The conjugated cyclopentene analog 22 exhibited activity with
low efficacy on FFA2 but again 100-fold selectivity over
FFA3 (Table 1). Thus, the series of conjugated unsaturated
SCAs preferentially activated the FFA2 receptor, and this was
achieved without substantial loss of LE.
General Rule for SCA Selectivity at FFA2 and FFA3 and
MolecularModeling of Binding Pocket—Close inspection of the
SAR data described above led us to hypothesize a general rule
governing SCA selectivity at FFA2 and FFA3. Overall, we found
that C1, C2, and all conjugated unsaturated carboxylic acids
exhibited substantial selectivity for FFA2, whereas the remain-
ing compounds exhibited selectivity for FFA3. Thus, we pro-
pose that ligands with sp2- or sp-hybridized -carbon preferen-
tially activate FFA2, whereas FFA3-selective ligands contain a
substituted sp3-hybridized -carbon. Furthermore, this rela-
tionship indicates that the binding pockets of FFA2 and FFA3
must be subtly different despite both receptors requiring the
same four basic amino acids for SCFA binding (18).
To examine themolecular determinants of SCA ligand selec-
tivity, we docked the FFA2-selective compound 20 (Fig. 5A)
and FFA3-selective compound 7 (Fig. 5B) into our molecular
models of the receptors. Because 12 also showed receptor-spe-
cific effects, albeit on efficacy rather than potency in the
[35S]GTPS assay, we also modeled 12 at FFA3 (Fig. 5C). We
have previously demonstrated that SCFA binding requires two
conserved arginine residues in both FFA2 and FFA3, ArgV:05/
5.39 andArgVII:08/7.35 (numbered according to the systems of
Schwartz and Baldwin (25, 41, 42) and Ballesteros and Wein-
stein (26)), which are presumed to act as anchoring residues for
the carboxylic acid on SCFAs (18). As expected, the carboxyl
group of each of the ligands is coordinating these arginines
in the models, and the ligands are placed in the cavity com-
FIGURE 4. Structure-activity relationships of conjugated unsaturated SCAs at FFA2 and FFA3. A, panels i–viii, DMR maximum response (pm) concentra-
tion-response curves to conjugated unsaturated SCAs were generated for either FFA2 (circles) or FFA3 (squares). Data are mean S.E., n 3. B, panels i–viii,
concentration-response curves of the same chemical series in IP1 (FFA2) and cAMP (FFA3) assays. Data are mean S.E., n 3.
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prising transmembrane helices 3, 5, and 6 (Fig. 5, A and B). In
particular, the SCA is surrounded by Tyr90(III:09/3.33),
Glu166(ECL2), Phe168(ECL2), Leu183(V:08/5.42), Cys184(V:09/
5.43), Tyr238(VI:16/6.51), and His242(VI:20/6.55) in hFFA2 and
by Phe96(III:09/3.33), Leu171(ECL2), Phe173(ECL2), Met188(V:
08/5.42), Ala189(V:09/5.43), Tyr241(VI:16/6.51), and His245(VI:
20/6.55) in hFFA3. We noted that the non-conserved residues
closest to the aliphatic moiety are residues at positions III:09/
3.33, V:08/5.42, and V:09/5.43 and Glu166/Leu171 in ECL2. The
aromatic residues at position III:09/3.33 form hydrophobic
interactions with the ligand; the tyrosineOHgroup at this posi-
tion in FFA2 is predicted to interact with the carboxyl group of
20. It is unlikely that this hydrogen-bond is crucial for binding,
however, because the conserved positively charged arginines
already anchor this group; thus, this residue is not thought to
contribute to ligand selectivity. Of the remaining non-con-
served residues within the predicted binding pocket, amino
acids at positions 5.42 and 5.43 are likely to provide hydropho-
bic interactions with the aliphatic moiety of the SCAs.
Glu166(ECL2) of FFA2 forms a salt bridge with Arg255(VII:08/
7.35), thereby coordinating the position of Arg255, whereas
Leu171(ECL2) of FFA3 has hydrophobic interactions with
ligands 7 and 12 (Fig. 5C). Because our SAR data indicated that
FFA3 preferred larger saturated or alicyclic moieties within the
SCAs compared with FFA2, which preferred flat unsaturated
moieties, we calculated the volume of the orthosteric binding
sites. In accordance with our SAR studies, we found that the
modeled binding site volume of FFA3 (105 Å3) is more than
double the volume of FFA2 (41 Å3). This difference may be due
to the presence of the non-conserved residues discussed earlier
as well as different residue packing caused by overall sequence
differences between the receptors. To verify that our models
and, therefore, our binding pocket hypotheses were predictive,
we next examined signaling at a series of orthosteric binding
site mutants.
Small Carboxylic Acids Bind to Orthosteric Binding Sites of
FFA2 and FFA3—Wehave previously demonstrated that SCFA
binding requires the two conserved arginine residues described
above (18). To establish whether the selective SCAs are also
accommodated within the orthosteric sites of FFA2 and FFA3,
respectively, and to confirm positioning of ligands 20, 7, and 12
in our molecular models, we examined the effect of these
ligands in [35S]GTPS binding assays following mutation of
either ArgV:05/5.39 or ArgVII:08/7.35 in FFA2 and FFA3.
Membranes were isolated from Flp-In T-REx 293 cells stably
expressing hFFA2 R180A(V:05/5.39)-eYFP, hFFA2 R255A(VII:
08/7.35)-eYFP, hFFA3 R185A(V:05/5.39)-eYFP, or hFFA3
R258A(VII:08/7.35)-eYFP in an inducible manner (18). For 20,
stimulation of wild type FFA2-eYFP but not hFFA2 R180A(V:
05/5.39)-eYFP or hFFA2 R255A(VII:08/7.35)eYFP membranes
resulted in [35S]GTPS incorporation (pEC50  4.17  0.09;
Fig. 6A), whereas no activity was observed at any of the forms
FIGURE 5. Molecular models of selective SCAs in orthosteric binding
sites of FFA2 and FFA3. A, molecular model of compound 20 in the puta-
tive FFA2 orthosteric binding site. B, compound 7 in FFA3 binding site.
C, compound 12 in FFA3 binding site. Ligand is represented by yellow
sticks, side chains of the residues forming the binding site only are shown
in green, and the backbone of the receptor is in ribbon style. The GPCR
residue notations of Schwartz and Baldwin (25, 41, 42) and Ballesteros and
Weinstein (26) are shown in parentheses.
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of FFA3 (Fig. 6B). Both arginine residues were also required for
activity of ligand 7 as mutation of either ArgV:05/5.39 or
ArgVII:08/7.35 prevented signal transduction at both FFA3
(pEC50  3.74  0.08 for wild type; Fig. 6C) and also FFA2
where it is a weak partial agonist (pEC50 3.05 0.09 for wild
type; Fig. 6D). Thus, it is clear that the carboxylic acid head
groups of the SCAs described here are also coordinating with
the positively charged arginines in the orthosteric binding site.
Examination of SCABinding Pocket at FFA2—To interrogate
the putative mode of binding of FFA2-selective ligands, we
replaced three non-conserved residues lining the FFA2 binding
site with the corresponding residues in FFA3. Bymaking such a
triple mutant receptor, we aimed to change the architecture of
the binding pocket tomore closely resemble that of FFA3 and, if
our hypotheses were correct, change the selectivity of ligands
acting at this receptor. Thus, the FFA2 residues Glu166(ECL2),
Leu183(V:08/5.42), and Cys184(V:09/5.43) were substituted by
the corresponding FFA3 residues Leu, Met, and Ala, respec-
tively (hereafter referred to as “FFA2 triple”) within the context
of hFFA2-eYFP (Fig. 7, A and B). Compounds 7 and 12 were
subsequently docked in the model of FFA2 triple, indicating
that mutation of these residues was consistent with facilitating
FFA3 ligand binding. We again calculated the volume of the
ligand binding site (this time at FFA2 triple) and found that
exchange of the FFA3 residues within FFA2 increased the vol-
ume of the orthosteric site (50 Å3), favoring accommodation of
the bulkier 7 (Fig. 7A) and 12 (Fig. 7B), which are now located
deeper within the pocket. Thus, to examine whether the triple
mutant could lead to reversal of ligand selectivity at FFA2, a
stable inducible Flp-In T-REx 293 cell line was established.
FFA2 triple expressionwas assessed using eYFP fluorescence as
a surrogate parameter and found to be at a level similar to wild
type hFFA2-eYFP and not significantly different fromwild type
hFFA3-eYFP (Fig. 7C).
As noted earlier, propionate is equipotent at FFA2 and FFA3
in the [35S]GTPS assay (Fig. 7D). Propionate potency at FFA2
triple was identical to wild type FFA2 and FFA3 (Fig. 7D), indi-
cating that thesemodifications to the orthosteric binding site of
FFA2 did not cause gross changes in receptor conformation.
Consistent with the Epic DMR assay data in Fig. 4A, 20 was
selective for FFA2 because it was inactive at FFA3 (Fig. 7E).
Critically, however, activity of 20 at FFA2 triple was markedly
impaired, suggesting that the binding pocket could no longer
effectively accommodate or be activated by this sp2 ligand (Fig.
7E). Because of their differing effects on selectivity and efficacy
in the [35S]GTPS assay, we also examined both 7 and 12 at the
FFA2 triple chimera. The highly selective and bulky compound
7 displayed100-fold selectivity for FFA3 over FFA2 (pEC50
3.76 0.26 at FFA3 and pEC50 1.65 0.17 at FFA2; Fig. 7F).
Mutation within the FFA2 orthosteric binding pocket was able
to rescue 7 function at FFA2 as this ligand displayed equivalent
potency at FFA2 triple and the FFA3 receptor (pEC50 3.80
0.12) (Fig. 7F), although full agonism was not achieved. Con-
versely, although ligand 12 was highly selective for FFA3 in the
DMR and second messenger assays (Fig. 3 and Table 1), in the
[35S]GTPS assay, it was equipotent at the wild type receptors
but differed in the magnitude of signal effect. Interestingly, this
poor efficacy at FFA2 wild type was completely reversed at
FFA2 triple with maximum activation even exceeding that of
wild type FFA3 (Fig. 7G). Thus, guided by developing a chemi-
cal rule for predicting specific activation of SCFA receptors and
in conjunction with molecular modeling and site-directed
mutagenesis, we were able to transfer FFA3 selectivity to FFA2.
FIGURE 6. Activity of selective SCAs at FFA2 and FFA3 orthosteric binding mutants. A and B, the FFA2-selective SCA 20 was assessed in the [35S]GTPS
binding assay at wild type (WT) FFA2-eYFP (A) or WT FFA3-eYFP (B) and the corresponding orthosteric binding site mutants R(V:05/5.39)A and R(VII:08/7.35)A
(amino acid and sequence number for each receptor construct is indicated in the key). C and D, the same orthosteric binding site mutants were assayed in
response to the FFA3-selective SCA, 7. Data are mean S.E., n 3.
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DISCUSSION
SCFAs are the endogenous ligands for both of the closely
related receptors FFA2 and FFA3, acting with similar potency
for all but the very shortest chain length SCFAs, C1 and C2 (1).
The physiological roles of the two receptors have largely been
based on studies with knock-outmice. The expression of FFA2,
however, was recently found to be reduced in FFA3 knock-out
mice, making it difficult to draw clear conclusions from these
studies (27). Limited endogenous ligand selectivity, the low
potency of these ligands, and the absence of selective
orthosteric compounds are therefore currently major obstacles
to the exploration of the physiological and pathological roles of
these receptors both in vitro and in vivo (15). In the present
study, we sought to address this issue by examining the molec-
ular determinants of ligand selectivity at FFA2. By screening a
targeted library of SCAs at FFA2 and counterscreening at FFA3
using the holistic Epic DMR biosensor assay, we discovered a
series of ligandswith selectivity for either receptor. SARanalysis of
the screening hits in combination with molecular modeling and
site-directedmutagenesis enabled formulation of a general chem-
FIGURE 7. Triplemutationwithin FFA2 orthosteric binding site confers FFA3 ligand selectivity to resulting receptor chimera. A and B, molecularmodel
of the hFFA2 E166L(ECL2)/L183M(V:08/5.42)/C184A(V:09/5.43)-eYFP chimeric receptor, FFA2 triple, showing docking of 7 (A) and 12 (B). C, expression of each
receptor was established by eYFP fluorescence where HEK293 autofluorescence was used as a negative control. RLU, relative light units. D–G, [35S]GTPS
binding was assessed for non-selective (C3;D), FFA2-selective (20; E), and FFA3-selective (7 and 12; F and G, respectively) SCAs at FFA2 triple. Responses were
compared with WT FFA2 and FFA3 in each experiment. Data are mean S.E., n 3.
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ical rule topredict receptorpreferenceofSCAs.Threeaminoacids
were identified as critical for selective orthosteric activation of
FFA2, and transfer of these residues to the binding pocket of FFA3
was sufficient to confer FFA3 ligand selectivity to the FFA2 recep-
tor. Our findings therefore provide the first description of the
determinants of selective orthosteric activation for FFA2.
Propionate is the most potent SCFA at both FFA2 and FFA3
and displays close tomaximal LE for both these receptors; i.e. it
is highly potent based on its size. Although increased potency
requires larger ligands, here we demonstrate that development
of small but selective ligands is indeed feasible. In fact, 20 and
21 represent two notable examples as they are both selective
and potent given their size. These two ligands are expected to
be instrumental for the design of novel selective orthosteric
FFA2 activators. A multifaceted program combining the vali-
dated molecular model of FFA2 described herein with frag-
ment-based drug discovery may facilitate the identification of
ligands with enhanced potency either by “growing” the ligands
stepwise or by linking the SCAs to fragments docked at acces-
sible positions within the receptor (13). In recent times, a series
of receptors have been shown to be activated by endogenous
smallmolecule ligands that aremore traditionally considered as
products of intermediary metabolism (28–31). All of these
ligands have modest potency at their target receptors, and the
concepts elucidated and discussed here may have general value
in the identification of selective and more potent orthosteric
agonists. This is particularly relevant as the potential therapeu-
tic implications of many of these receptors, e.g. GPR109A,
clearly define a need to develop potent and selective agonists
rather than antagonists (32, 33).
Awell defined shapewas a criterion for selection of screening
compounds to facilitate SARanalysis andmodeling. Apart from
C5, they only have zero to two rotatable bonds (defined as the
number of non-cyclic single bonds where rotation leads to a
change in the position of non-hydrogen atoms relative to the
remaining molecule; e.g. 14 has zero rotatable bonds). These
ligands adopt a very limited number of possible conformations
and are therefore ideally suited for modeling and docking stud-
ies at the FFA2 binding site. Indeed, evidence of the accuracy of
our FFA2 model and SCA docking is provided by the fact that
we were able to identify the anchoring arginines for the carbox-
ylic acid group in transmembrane domain V and transmem-
brane domain VII and transfer ligand selectivity between FFA2
and FFA3 by exchanging just three key amino acids. Very few
examples of such a transfer of ligand selectivity between GPCR
binding sites have been described. A notable example is the
transfer of the binding of AMD3100 from CXCR4 to CXCR3
achieved by a doublemutation and the presence of two essential
aspartates conserved in both receptors (34).
It is well known from a number of studies that receptor phar-
macology may vary depending on the cellular context and the
signaling end point under investigation (35–38). The SCFA
receptors examined herein are known to engage with Gi/o
family proteins (FFA3) or with both Gi/o and Gq/11 (FFA2).
This implies that, at least for FFA2, ligands may be identified
with preference for individual signaling pathways. To rule out
the possibility that so-called biased ligands may escape detec-
tion when using a single functional end point assay, one can
either gather biological information by testing compounds in
several parallel assays or rather use one of the novel, label-free
assay technologies that capture whole cell responses in a man-
ner comparable with tissue bioassays (24, 39, 40). The latter
may also have the advantage that ligand activity will reflect an
integrated response of a living cell rather than a readout deter-
mined in isolation and underappreciative of intertwined signal-
ing networks that overlap in time and space. In our study, we
took advantage of the Corning Epic biosensor, which translates
receptor activation into real time optical traces in a pathway-
unbiased yet pathway-sensitive manner (19) and chose this
method for primary screening. Hit confirmation was per-
formed with classical biochemical ([35S]GTPS) or second
messenger (cAMP and IP1) assays as validation. Themajority of
hits identified using the holistic approach were also confirmed
in the classical assays. However, we also noted the existence of
compounds such as 10 with activity in the Epic but complete
inactivity in [35S]GTPS binding assays. Lack of [35S]GTPS
incorporation induced by 10 at FFA2 might be explained by its
inability to engage Gi/o signaling; however, inactivity at FFA3
of 10 is hard to rationalize given that activity was also detected
in parallel cAMP inhibition assays. Hence, it is possible that the
receptor-proximal [35S]GTPS binding assay is simply not sen-
sitive enough to identify activators with poor potency and effi-
cacy because this is likely to be linked closely to receptor occu-
pancy, whereas more distal signals, such as those measured in
the DMR assay, often provide substantial amplification and
receptor reserve (39). In contrast, 2 was hardly active in DMR
assays on either receptor but appeared to be a high efficacy
agonist in GTPS binding. As DMR is an integrated signal, the
absence of positiveDMR for2may reflect additional but oppos-
ing cellular events triggered by this compound. Overall, these
data demonstrate the strength of combining traditional end
point with novel holistic assays to unravel mechanistic differ-
ences of compounds that would remain unexploredwhen using
either method in isolation.
It is interesting that introduction of an alkene or alkyne con-
jugated with the carboxylic acid in the SCAs consistently
reversed FFA receptor selectivity and that FFA2 was able to
accommodate and respond to larger compounds provided that
they contained this conjugated unsaturation. Acrylate (13) is
the parent compound of most of these and has agonist activity
comparable with C3 yet preferentially activates FFA2 over
FFA3. All substituted acrylates (16-22) were FFA2 agonists and
showed preference or in most cases significant selectivity for
FFA2 over FFA3. These results indicate that the binding pocket
of FFA2 has a narrow shape, and steric restrictions apply in the
area around the -carbon atoms of the SCFAs. The preferred
planar structure around the carboxylic acid due to conjugation
is likely to be a significant factor in FFA2 selectivity. These
observations have led to the identification of a general rule to
predict FFA2 versus FFA3 selectivity of small (6 carbon
atoms) carboxylic acids with lipophilic tails: compounds carry-
ing an sp2- or sp-hybridized -carbon will be FFA2-selective,
whereas compounds carrying a substituted sp3-hybridized
-carbon will be FFA3-selective. The rule has proven highly
predictive, and we have yet to observe any exceptions.
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In summary, the first series of molecular tools selectively
activating FFA2 via the orthosteric binding site was provided,
and many of these ligands showed close to optimal ligand effi-
ciencies. Hence, it is possible to achieve selective activation of
FFA2 versus FFA3 with rather small ligands. Such ligands will
undoubtedly be useful to further explore the mechanism of
activation of FFA2 inmore detail or its signaling characteristics
in vitro even in cells coexpressing the related FFA3. Future
studies are needed to unravel whether selectivity can be main-
tained within molecules that are gradually increased in size to
also achieve a gain of potency that will be a prerequisite to
explore the role of FFA2 in vivo. Nevertheless, our results pro-
vide, for the first time, a molecular explanation for selective
orthosteric activation of FFA2 by highlighting previously
unrecognized determinants of selectivity within the orthosteric
binding site.
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